VOR33 granted U.S. FDA fast track designation for AML

9 September 2021 - Vor Biopharma today announced that the U.S. FDA has granted fast track designation to VOR33, the ...

Read more →

MSAC publishes agenda for upcoming meeting

3 September 2021 - 12 agenda items for consideration at the 25-26 November 2021 meeting. ...

Read more →

CAR-T therapy Kymriah fails to get insurance benefits

2 September 2021 - The first CAR-T therapy, Kymriah (ingredient: tisagenlecleucel), failed to pass the review of a panel at ...

Read more →

Bristol Myers Squibb receives European Commission approval for Abecma (idecabtagene vicleucel), the first anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma

19 August 2021 - Abecma represents the only cell therapy approved for multiple myeloma. ...

Read more →

Quality assurance requirements of the G-BA also apply to new CAR-T cell therapy

5 August 2021 - The Federal Joint Committee (G-BA) today evaluated the new cancer drug with the trade name Tecartus and ...

Read more →

Lymphoma patients to benefit from new cancer therapy

5 August 2021 - Australians suffering from a rare type of blood cancer will now have access to a highly specialised ...

Read more →

New CAR T-cell therapy option now available in Australia for patients with aggressive blood cancer

5 August 2021 - Eligible patients can now access Yescarta through Peter MacCallum Cancer Centre, Melbourne and Royal Brisbane and Women’s ...

Read more →

bluebird bio receives EC approval for Skysona (elivaldogene autotemcel, Lenti-D) gene therapy for patients less than 18 years of age with early cerebral adrenoleukodystrophy without matched sibling donor

21 July 2021 - Skysona is the first and only gene therapy approved in the European Union to treat early CALD. ...

Read more →

Leukaemia patients demand reimbursement for Novartis’ Kymriah

12 July 2021 - Korean leukaemia patients have urged the government to provide rapid reimbursement of Kymriah, the first CAR-T ...

Read more →

NICE publishes draft guidance on the use of Libmeldy

9 July 2021 - OTL-200 (Libmeldy) is a gene therapy medicinal product that expresses the human ARSA gene. ...

Read more →

Allogene Therapeutics granted FDA fast track designation for ALLO-605, the first TurboCAR T Cell therapy, for the treatment of relapsed/refractory multiple myeloma

30 June 2021 - TurboCAR technology provides selective, programmable cytokine signaling designed to improve function and potency of AlloCAR T cells. ...

Read more →

Bristol Myers Squibb receives positive CHMP opinion for anti-BCMA CAR T cell therapy Abecma (idecabtagene vicleucel) for relapsed and refractory multiple myeloma

25 June 2021 - Recommendation for approval based on results from pivotal KarMMa study. ...

Read more →

China's first CAR-T cell therapy approved Fosun Kite axicabtagene ciloleucel (FKC876)

24 June 2021 - The first CAR-T cell therapy approved by NMPA: opening a new era of cell therapy in China. ...

Read more →

FDA approves StrataGraft for the treatment of adults with thermal burns

15 June 2021 - Today, the U.S. FDA approved StrataGraft for the treatment of adult patients with thermal burns containing intact ...

Read more →

Health Canada approves Abecma (idecabtagene vicleucel), the first and only anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma

31 May 2021 - Abecma is the first personalised cell therapy available to Canadian patients for the treatment of adults ...

Read more →